Paravalvular Leak After TAVR: Close It Now or Watch It
A single patient whose new post-TAVR finding carries real long-term risk, found on a routine echo well before any symptom appeared.
A.M., a 79-year-old woman, spent thirty-one years as an elementary school principal before retiring, and she says the habit of noticing small things before they become big problems never really left her — which made her unusually calm, rather than alarmed, when her cardiologist raised a new finding on a routine follow-up visit she'd expected to be a formality.
She underwent TAVR eight months ago for severe aortic stenosis and has done clinically well since — no breathlessness, no chest discomfort, back to her regular routine within weeks of the procedure. Her routine follow-up echocardiogram, performed as part of standard post-TAVR surveillance, showed a mild-to-moderate paravalvular leak that was not present on the echocardiogram taken immediately after her procedure — a genuinely new finding, not something missed earlier. She has no heart failure symptoms and no evidence of hemolysis on bloodwork. She takes low-dose aspirin alone, the expected long-term antithrombotic after transcatheter replacement in someone with no separate indication for anticoagulation — relevant here because any escalation of antithrombotic therapy would raise, not lower, the risk of the hemolysis a paravalvular leak can produce.
Paravalvular leak of this degree occupies a real gray zone in current practice: percutaneous closure is an established option with a reasonable safety profile, and some data links even moderate PVL to worse long-term outcomes — more heart failure hospitalizations and higher late mortality — even before symptoms develop, which is part of why some interventionalists favor addressing it before waiting for those consequences to appear. Closure also tends to become more technically complex the longer it's deferred, as the leak's anatomy can change. Set against that is the real procedural risk of an additional intervention in a 79-year-old with no current symptoms to justify it.
A leak with no symptoms yet to justify acting on
I'd favor earlier closure rather than waiting for symptoms. The data linking even moderate paravalvular leak to worse late outcomes doesn't require her to be symptomatic first — by the time heart failure or hemolysis develops, some of that damage has already accumulated. Closure also tends to get technically harder the longer it's deferred, so waiting isn't a neutral choice; it has its own cost.
I'd favor conservative monitoring for now. She's asymptomatic, with preserved function and no hemolysis — by every measure we have today, she's doing well. I don't want to expose a 79-year-old to the procedural risk of a second intervention for a leak that may remain stable, when we have a straightforward way to watch for exactly the changes that would tell us it isn't.
At her age, I'd weight her own priorities as heavily as the outcomes data. She's independent and active, and what she wants to avoid — whether that's another procedure or the long-term risk of leaving this unaddressed — matters as much here as which approach has marginally better population-level numbers. I'd want her voice explicitly in this decision, not just ours.
Conservative monitoring adopted, with echocardiographic follow-up at three months and explicit triggers defined for revisiting closure: any hemolysis, any symptom onset, or progression of the leak on follow-up imaging.
Conservative monitoring continues, with surveillance intervals reassessed based on that stability.
Percutaneous closure moves from a held-in-reserve option to an active recommendation.
The structural cardiologist's concern about outcomes data tied to even asymptomatic PVL was never dismissed — it shaped the specific triggers the team built into the surveillance plan — but the group ultimately gave more weight to her current stability and her own stated preference to avoid another procedure unless and until something changes.